BioSpace News Archive

CooperCompanies announced financial results for its fiscal first quarter ended January 31, 2021.

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the year ended December 31, 2020.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and year ended December 31, 2020 on March 10, 2021 after the market close.

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that Paul R.

Immersion Corporation, the leading developer and provider of technologies for haptics, reported financial results for the fourth quarter ended December 31, 2020.

ReWalk Robotics Ltd. announced that Larry Jasinski, Chief Executive Officer and Ori Gon, Chief Financial Officer will present at H.C.WAINWRIGHT global life science conference held on March 9 – 10, 2021.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that results of the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) have been selected for presentation at the upcoming American Academy of Neurology (AAN) annual meeting, being held virtually April 17 – 22, 202

SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies without the need for human serum, today announced that Eddie J. Sullivan , PhD, co-founder, president and CEO, will present at two upcoming investor conferences.

KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will present at the 33rd Annual Roth Conference being held virtually from March 15-17, 2021.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva”) today announced that its wholly owned subsidiary Reviva Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, will present at the H.C. Wainwright Global Life Sciences Conference,